10-K: Creative Medical Tech Reports 2025 Losses, Advances Clinical Pipeline

Creative Medical Technology Holdings, Inc. reported increased net losses for 2025 despite significant clinical trial advancements and successful capital raises, highlighting ongoing R&D investment.

Summary

• Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company focused on regenerative therapies in immunotherapy, endocrinology, urology, neurology, and orthopedics.
• The company reported a net loss of $5,995,008 for the year ended December 31, 2025, an increase from $5,493,481 in 2024.
• Gross revenue decreased by 46% to $6,000 in 2025 from $11,000 in 2024, primarily from CaverStem sales.
• Research and development expenses slightly decreased to $2,259,796 in 2025 from $2,400,777 in 2024.
• Selling, general and administrative expenses increased by 16% to $3,763,497 in 2025 from $3,239,232 in 2024.
• The company successfully completed patient enrollment for the CELZ-201 ADAPT clinical trial for chronic lower back pain in December 2025.
• FDA Fast Track designation was granted to CELZ-201-DDT in August 2025, and Orphan Drug Designation was received for Brittle Type 1 Diabetes using ImmCelz (CELZ-100) in March 2024.
• Expanded its agreement with Greenstone Biosciences Inc. in February 2025 to leverage AI for its iPSC platform in diabetes treatment and launched the BioDefense Veterans Initiative in October 2025.
• Raised approximately $7.9 million in gross proceeds from warrant exercises in March and October 2025.
• Cash and short-term U.S. treasuries stood at approximately $7.2 million as of December 31, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report for a clinical-stage biotech. While financial losses persist and commercial revenue is minimal, the significant progress in multiple clinical trials, receipt of key FDA designations (Fast Track, ODD), and successful capital raises to fund operations demonstrate strong pipeline advancement and investor confidence in its long-term potential.

Positives

• Successfully developed a viral-free human induced pluripotent stem cell (iPSC) line (iPScelz) in May 2023, estimated to save two to three years in research and development time and associated expenses.
• Received FDA clearance for the Type I Diabetes (CELZ-201 CREATE-1) Investigational New Drug (IND) application in November 2022, enabling the initiation of a Phase I/II clinical trial.
• Reported positive three-year follow-up data for its StemSpine pilot study in February 2023, demonstrating continued efficacy (87% efficacy rate) for treating chronic lower back pain without serious adverse effects.
• ImmCelz (CELZ-100) platform demonstrated 75% fewer donor patient cells, greater than 95% purity (compared to industry standard of greater than 80%), and a greater than 200% reduction in functional suppression of effector T cells in independent studies reported in March 2023.
• Received Orphan Drug Designation (ODD) from the FDA for the treatment of Brittle Type 1 Diabetes using its ImmCelz (CELZ-100) platform in March 2024, providing benefits like tax advantages, user fee exemptions, and potential market exclusivity.
• Reported positive one-year follow-up data in April 2023 for CELZ-001 in Type 2 Diabetes patients, showing 93% efficacy in reducing insulin requirement by at least 50% with no safety concerns.
• Received FDA clearance in September 2023 to initiate a Phase I/II clinical trial of AlloStemSpine Chronic Lower Back Pain (CELZ-201 ADAPT).
• Secured FDA authorization in March 2024 for an expanded access therapy using CELZ-201 for managing abnormal glucose tolerance and preventing Type I Diabetes in high-risk individuals, believed to be a medical first.
• Successfully generated human induced pluripotent stem cells (iPSC)-derived islet cells that produce human insulin in June 2024, with potential for clinical translation.
• Completed an independent interim safety review by the Data Safety Monitoring Board (DSMB) for the CELZ-201 ADAPT clinical trial in November 2024, concluding the trial may proceed as planned.
• Announced promising initial data from the first cohort of the CELZ-201 ADAPT clinical trial in January 2025, with no dose-limiting toxicities or serious adverse events and encouraging therapeutic potential.
• Expanded its agreement with Greenstone Biosciences Inc. in February 2025 to leverage Artificial Intelligence (AI) in further developing its human iPSC platform for diabetes treatment, including multi-gene editing.
• FDA cleared an expanded dose escalation for its ongoing Phase 1/2 trial of StemSpine using AlloStem (CELZ-201-DDT) in March 2025, following compelling interim blinded data.
• FDA granted Fast Track designation to its lead investigational therapy, CELZ-201-DDT, in August 2025, potentially expediting the path to market.
• Launched the BioDefense Veterans Initiative in October 2025, combining AI with proprietary iPSC to combat long-term effects of toxic burn pit exposure, with Greenstone Biosciences as an exclusive partner.
• Successfully completed patient enrollment in the ADAPT clinical trial evaluating CELZ-201 (Olastrocel) in December 2025.
• Generated $3.7 million and approximately $4.2 million in gross proceeds from warrant exercise inducement agreements in March and October 2025, respectively.
• Cash and short-term U.S. treasuries increased to $7,208,126 as of December 31, 2025, from $5,940,402 in 2024.

Negatives

• Incurred an operating loss of approximately $6.1 million for the year ended December 31, 2025, compared to $5.7 million in 2024.
• Reported a net loss of $5,995,008 for 2025, an increase from the $5,493,481 loss in 2024.
• Gross revenue decreased by 46% to $6,000 in 2025 from $11,000 in 2024, primarily due to a decrease in CaverStem sales.
• Management is re-evaluating the marketing strategy for the CaverStem and FemCelz products due to minimal revenues generated.
• Selling, general and administrative expenses increased by 16% to $3,763,497 in 2025.
• Other income decreased by 41% to $147,806 in 2025, primarily due to a reduced average balance and lower interest rates on short-term U.S. treasuries.
• Net cash used in operating activities increased by $555,153 to $5,856,445 in 2025, primarily related to increased operating expenses.
• Autologous products like CaverStem and FemCelz are currently not eligible for reimbursement from public or private insurers, limiting their market to patients who can pay directly.

Risks

• The company has a history of losses and its future profitability is uncertain, expecting operating losses to continue until sufficient revenue is generated.
• Additional capital will be needed to fund operations, research and development programs, clinical trials, regulatory approvals, and product manufacturing and marketing.
• Future offerings of common stock or other securities could cause substantial dilution of current stockholders' percentage ownership and adversely affect the stock price.
• Minimal revenues have been generated from products, and significant financial losses are expected to continue as clinical trials proceed.
• The commercial viability of product candidates is subject to successful preclinical studies, clinical trials, and regulatory approvals, with no assurance of success.
• Commercialization efforts for proposed products and therapies may not achieve sufficient market acceptance by physicians, patients, and healthcare payors.
• Clinical trial results may not support product claims, may not be replicated, or may lead to the discovery of adverse side effects, potentially delaying or terminating development.
• Limited experience in conducting and managing clinical trials necessary for obtaining regulatory approvals, relying heavily on third-party CROs.
• Clinical trials are lengthy, expensive, and have uncertain outcomes, with potential for unforeseen events to cause delays or prevent commercialization.
• Autologous products are currently not eligible for reimbursement from public or private insurers, limiting market access.
• The pharmaceutical business is subject to increasing government regulation and reform, including price controls and reimbursement, which could adversely affect future revenues and profitability.
• United States federal and state privacy laws, and equivalent foreign laws, may increase operating costs and expose the company to civil and criminal sanctions.
• Later discovery of previously unknown problems with products, manufacturing processes, or non-compliance with regulatory requirements could limit marketability or lead to product liability claims.
• Failure to obtain required approvals in other countries would limit international market opportunities.
• Reliance on third parties for research and clinical trials means less control over timing and execution, and their failure to perform could delay regulatory approval.
• A very limited marketing and sales organization means significant resources must be invested or third-party agreements secured to generate sufficient revenues.
• Reliance on third parties for the manufacture of disposable kits carries risks related to quality and effectiveness.
• Intense competition from established pharmaceutical, biotechnology, and medical device companies with greater financial resources and expertise.
• Computer system failures or security breaches could adversely affect business operations, lead to loss of confidential information, and delay product development programs.
• Global outbreaks (e.g., COVID-19) and wars (e.g., Ukraine, Gaza Strip) pose risks to business activities, supply chains, and the ability to raise capital.
• Inability to protect proprietary rights, including patents and trade secrets, or susceptibility to intellectual property suits, could harm the ability to compete.
• Dependence on executive officers (Timothy Warbington, Donald Dickerson) means their loss could adversely affect business strategy.
• Risk of fraud or other misconduct by employees, clinical trial investigators, CROs, consultants, vendors, and commercial partners, leading to regulatory sanctions or reputational harm.
• Failure to comply with the U.S. federal Anti-Kickback Statute and similar state and foreign laws could result in criminal and civil penalties and exclusion from federally funded healthcare programs.
• The market price of common stock is highly volatile, and there is a risk of delisting from The Nasdaq Capital Market if continued listing requirements are not met.
• No dividends are expected to be paid for the foreseeable future, making the stock unsuitable for investors seeking cash dividends.

Future Outlook

The company expects operating losses to continue until product sales, licensing fees, and royalties generate sufficient revenue to fund operations. Expenses are anticipated to increase substantially with ongoing and future preclinical studies, clinical trials, marketing approvals, and the establishment of a sales and marketing infrastructure. Clinical trials for Type I Diabetes (CELZ-201 CREATE-1) and AlloStemSpine Chronic Lower Back Pain (CELZ-201 ADAPT) are estimated to continue for several years. The company believes it will have sufficient cash to meet anticipated operating costs and capital expenditure requirements through at least March 2027, but anticipates needing to raise additional capital in the future through securities sales to fund ongoing operations and clinical trials.

Management Comments

• We believe this process endows the immune cells with regenerative properties (or supercharges them) providing them with the ability to treat multiple indications.
• We estimate that the development of this cell line will save the Company two to three years in research and development time along with associated expenses.
• We believe these results show that we will be able to substantially reduce production costs, while allowing for the manufacture of the best clinical product for patients with immune disorders, which will enable us to accelerate our clinical applications and encourage potential collaborations with respect to our ImmCelz platform.
• This trial, protected by issued patents, is a huge milestone for the Company and for patients suffering from this debilitating problem and their need for opioids for pain.
• The Company believes this development has the potential for not only clinical translation of the human Islet Cells, but also the stand-alone human insulin which is produced by these cells.
• Management is currently re-evaluating the marketing strategy for the Caverstem and FemCelz products. We are exploring options to achieve market penetration and product profitability with a number of potential partners.
• We believe we will have sufficient cash to meet our anticipated operating costs and capital expenditure requirements through at least March 2027.

Industry Context

StockSavvy.ai notes that Creative Medical Technology Holdings operates in the highly competitive and rapidly evolving regenerative medicine sector, characterized by significant R&D investment and regulatory hurdles. The company's focus on diverse therapeutic areas (immunotherapy, endocrinology, urology, neurology, orthopedics) with stem cell and iPSC platforms aligns with broader industry trends towards personalized and advanced cell-based therapies. The strategic partnerships with Greenstone Biosciences for AI-driven iPSC development and the BioDefense Veterans Initiative demonstrate an effort to leverage cutting-edge technologies and address high-unmet-need areas, potentially differentiating it from competitors. However, the industry also faces challenges in commercialization and reimbursement, as highlighted by the company's re-evaluation of its existing autologous products.

Comparison to Industry Standards

• The ImmCelz (CELZ-100) platform required 75% fewer donor patient cells compared to industry standard.
• The purity of the final ImmCelz (CELZ-100) product was greater than 95% compared to the industry standard of greater than 80%.
• ImmCelz (CELZ-100) demonstrated a greater than 200% reduction in functional suppression of effector T cells, which are a critical concern for patients with autoimmune issues, while still possessing a high number of functional T regulatory cells.
• For regenerative medicine in disc and spine, the company's treatment is injected around the disc, contrasting with competitors like Mesoblast, Longeveron, BioRestorative Therapies, and DiscGenics, which often inject into the disc. Mesoblast Limited has reported patient follow-ups as long as three years post-injection showing some degree of pain reduction and disc regeneration without adverse effects.

Corporate Governance

Legal Proceedings

• The company may become involved in various lawsuits and legal proceedings in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result could harm the business.

Related Party Transactions

• The company acquired U.S. Patent No. 9,598,673 for lower back pain from Creative Medical Health, Inc. (CMH), a related company. Payments to CMH included $100,000 for IND filing in August 2023 and $200,000 for dosing the first patient in a Phase 1-2 clinical trial in August 2024.
• ImmCelz, Inc., a subsidiary, entered into a Patent License Agreement with Jadi Cell, LLC, a company owned and controlled by Dr. Amit Patel, a former director. An initial license fee of $250,000 was paid by issuing 18,018 shares of common stock in February 2022.
• Timothy Warbington, the company's Chief Executive Officer, purchased one share of Series B Preferred Stock for $100 on May 14, 2024, which was later redeemed. As of December 31, 2025, the $100 is payable to the CEO and included in accounts payable.
• The company contributed $43,200 to Bionance, LLC, a subsidiary where it holds an 80% interest. Timothy Warbington (CEO) contributed $10,800 to Bionance. The Managing Member of Bionance Management LLC is owned in equal parts by Mr. Warbington, Donald Dickerson (CFO), and Dr. Amit Patel (consultant).

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and market price volatility, with no dividends expected in the foreseeable future, but could see long-term value creation if the clinical pipeline succeeds.
• Patients stand to benefit from the development of regenerative therapies for various conditions, including erectile dysfunction, female sexual dysfunction, chronic lower back pain, Type 1 and Type 2 diabetes, premature ovarian failure, neurological conditions, heart, liver, and kidney failure, and burn pit exposure.
• Employees, particularly the executive management team, are critical to the company's success, and there is a risk of misconduct by employees, clinical trial investigators, and other partners.
• Customers (physicians) for current autologous products like CaverStem and FemCelz are limited to patients who can pay directly, as these procedures are not eligible for public or private insurance reimbursement.
• Creditors may view the company's ongoing financial losses and continuous need for additional capital as a risk, although the current cash position is deemed sufficient through at least March 2027.

Next Steps

• Continue clinical trials for Type I Diabetes (CELZ-201 CREATE-1) and AlloStemSpine Chronic Lower Back Pain (CELZ-201 ADAPT) for several years.
• Enroll the second cohort in the CELZ-201 ADAPT trial (expected in Q1 2025, as per the filing's forward-looking statement).
• Conduct comprehensive data analysis from subsequent cohorts of the ADAPT trial to guide future clinical and regulatory plans.
• Seek marketing approvals for product candidates that successfully complete clinical trials.
• Establish a sales, marketing, and distribution infrastructure to commercialize products for which marketing approval may be obtained.
• Further develop cell platforms and file Investigational New Drug (IND) applications for additional indications that utilize these platforms.
• Evaluate other collaborators, partners, and business opportunities to accelerate development without detracting from core clinical programs.
• Continue to raise additional capital through the sale of securities from time to time to fund future operational and development initiatives.
• Management is re-evaluating the marketing strategy for the CaverStem and FemCelz products to achieve market penetration and profitability.

Key Dates

Recommendation

Creative Medical Technology Holdings is a high-risk, high-reward clinical-stage biotechnology company. While it continues to incur significant losses and has minimal commercial revenue, the substantial progress in its diverse clinical pipeline, including multiple FDA designations (Fast Track, Orphan Drug), positive interim clinical data, and successful capital raises to fund operations, indicates strong operational momentum. The strategic partnerships leveraging AI and iPSC technology are promising. However, the long and uncertain path to commercialization, ongoing need for capital, and inherent risks of clinical development warrant a 'Hold' recommendation for investors who are comfortable with high volatility and long-term investment horizons, awaiting further definitive clinical outcomes and clearer paths to market.

Keywords

Regenerative medicine, Biotechnology, Stem cells, Immunotherapy, Endocrinology, Urology, Neurology, Orthopedics, Clinical trials, FDA approval, Orphan Drug Designation, Fast Track designation, Artificial Intelligence, iPSC, Diabetes treatment, Lower back pain, Burn pit exposure, Capital raise, Warrants, SEC filing, 10-K, CELZ-201 ADAPT, ImmCelz, AlloStem, iPScelz